TY  - GEN
AU  - Cheng,Ann-Lii
AU  - Thongprasert,Sumitra
AU  - Lim,Ho Yeong
AU  - Sukeepaisarnjaroen,Wattana
AU  - Yang,Tsai-Shen
AU  - Wu,Cheng-Chung
AU  - Chao,Yee
AU  - Chan,Stephen L
AU  - Kudo,Masatoshi
AU  - Ikeda,Masafumi
AU  - Kang,Yoon-Koo
AU  - Pan,Hongming
AU  - Numata,Kazushi
AU  - Han,Guohong
AU  - Balsara,Binaifer
AU  - Zhang,Yong
AU  - Rodriguez,Ana-Marie
AU  - Zhang,Yi
AU  - Wang,Yongyu
AU  - Poon,Ronnie T P
TI  - Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
SN  - 1527-3350
PY  - 2017///0802
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Animals
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Benzimidazoles
KW  - Biomarkers
KW  - blood
KW  - Carcinoma, Hepatocellular
KW  - Cell Line, Tumor
KW  - Asia, Eastern
KW  - epidemiology
KW  - Female
KW  - Humans
KW  - Liver Neoplasms
KW  - Male
KW  - Mice, Inbred BALB C
KW  - Mice, Inbred C57BL
KW  - Mice, Nude
KW  - Middle Aged
KW  - Niacinamide
KW  - Phenylurea Compounds
KW  - Quinolones
KW  - Sorafenib
KW  - Treatment Outcome
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1002/hep.28600
ER  -